Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered Viracta (VRx)-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies

Next Previous
Trial Profile

A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered Viracta (VRx)-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nanatinostat/valganciclovir combination therapy (Primary) ; Valganciclovir (Primary)
  • Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Hodgkin's disease; Lymphoproliferative disorders; Peripheral T-cell lymphoma; Post-transplant lymphoproliferative disorder; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Viracta Therapeutics

Most Recent Events

  • 04 Oct 2023 According to a Viracta Therapeutics media release, company's plans to highlight new preliminary clinical data from this study during an R&D Day.
  • 08 Aug 2023 According to a Viracta Therapeutics media release, data published from this trial supports the recently announced expansion of EBV-positive peripheral T-cell lymphoma cohort, representing an exciting time for clinical trial program and the company look forward to providing more updates on its progress in the future.
  • 08 Aug 2023 According to a Viracta Therapeutics media release, results from this trial were published in the Blood Advances.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top